Journal of the American Academy of DermatologyReview
undefined Dec 2024
In the second part of this CME, we present an approach for the management of inflammatory and vaso-occlusive ulcers and highlight the need for further research in this field.
The 3 overarching principles for management are etiology-specific treatment, ulcer care, and consideration of patient comorbidities and risk factors for poor healing.
Both etiology-specific treatment and management of patient comorbidities and risk factors often require collaboration with providers from other specialties. Ulcer care is governed by tissue debridement, infection control, management of moisture imbalance, and epithelial edge advancement.
As wound healing is a dynamic process, management should be adapted to changes in the status of the ulcer.
Conflicts of interest Dr Fett is on the board of the Medical Dermatology Society and serves as the education cochair for the MDS. Dr Fett is an author and editor for UpToDate vasculitis, lichen sclerosus, and pyoderma gangrenosum topics. Dr Alavi serves as the board member of HS foundation and as principal investigator for BI (Boehringer Ingelheim) and Processa and consultant for Abbvie, BI, InflaRx, Novartis, UCB. Dr Ortega is the current President of the Pacific Dermatology Association and serves as an associate editor for Dermatology (Karger). Additionally, he is a consultant for Genentech and Guidepoint and an advisor to Bristol Meyer Squibb, Boehringer Ingelheim and Janssen. Dr Ortega has received research grants from the Lilly, Janssen, Incyte and Pfizer. He is supported by NIH NIAMS R01 AR083110. The other authors have no conflicts of interests to disclose.
More resources:
Share: